Last $13.98 USD
Change Today -0.01 / -0.07%
Volume 44.8K
RDSMY On Other Exchanges
Symbol
Exchange
OTC US
EN Amsterdam
OTC US
Frankfurt
As of 8:10 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

koninklijke dsm nv-spons adr (RDSMY) Snapshot

Open
$13.97
Previous Close
$13.99
Day High
$14.04
Day Low
$13.96
52 Week High
05/6/14 - $18.50
52 Week Low
01/15/15 - $12.36
Market Cap
10.1B
Average Volume 10 Days
42.5K
EPS TTM
--
Shares Outstanding
725.7M
EX-Date
08/13/14
P/E TM
--
Dividend
$0.36
Dividend Yield
4.10%
Current Stock Chart for KONINKLIJKE DSM NV-SPONS ADR (RDSMY)

Related News

No related news articles were found.

koninklijke dsm nv-spons adr (RDSMY) Related Businessweek News

View More BusinessWeek News

koninklijke dsm nv-spons adr (RDSMY) Details

Koninklijke DSM N.V. operates as a life sciences and materials sciences company worldwide. The company operates in five segments: Nutrition, Pharma, Performance Materials, Polymer Intermediates, and Innovation Center. It manufactures food enzymes, cultures, savory ingredients, and other specialties, as well as nutritional products, such as vitamins, carotenoids, eubiotics, feed enzymes, premixes, nutritional lipids, and cultures for the food and beverage, feed, personal care, dietary supplements, and pharmaceutical industries. The company also provides custom manufacturing and development services to the pharmaceutical, biopharmaceutical, and agrochemical industries; and beta-lactam active pharmaceutical ingredients, such as semi-synthetic penicillins and semi-synthetic cephalosporins, as well as nystatin. In addition, it offers engineering thermoplastic solutions; Dyneema, a strong fiber; and resins solutions for paints and coatings, composite materials, and optical fiber coatings. Further, the company produces caprolactam and acrylonitrile that are raw materials for synthetic fibers and plastics; and other products, including ammonium sulfate, sodium cyanide, cyclohexanone, and diaminobutane. Additionally, it develops materials-based solutions comprising coatings, drug delivery platforms, and a range of biomedical materials for medical device and biopharmaceutical industries; creates solutions for bioconversion of feedstocks for the production of bio-energy, such as cellulosic biofuels, as well as bio-based chemicals and materials; and provides smart coatings and surface technologies to the solar industry. The company was founded in 1902 and is headquartered in Heerlen, the Netherlands.

21,351 Employees
Last Reported Date: 02/11/15
Founded in 1902

koninklijke dsm nv-spons adr (RDSMY) Top Compensated Officers

Chairman of Managing Board, Chief Executive O...
Total Annual Compensation: €1.4M
Member of The Managing Board
Total Annual Compensation: €954.0K
Member of Managing Board
Total Annual Compensation: €887.0K
Member of The Managing Board
Total Annual Compensation: €268.0K
Compensation as of Fiscal Year 2013.

koninklijke dsm nv-spons adr (RDSMY) Key Developments

Royal DSM N.V. Reports Unaudited Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Ebitda Guidance for the Year 2015

Royal DSM N.V. reported unaudited earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported net sales of EUR 2,374 million against EUR 2,175 million a year ago. EBITDA was EUR 288 million against EUR 297 million for the same period a year ago. Core net profit, continuing operations was EUR 112 million against EUR 118 million a year ago. Net profit before exceptional items, continuing operations was EUR 89 million against EUR 101 million a year ago. Net loss after exceptional items, total DSM was EUR 107 million or EUR 0.63 per share against EUR 77 million or EUR 0.46 per share a year ago. Core EPS was EUR 0.65 against EUR 0.68 a year ago. Net EPS before exceptional items, continuing operations was EUR 0.52 against EUR 0.57 a year ago. Cash flow from operations was EUR 418 million against EUR 476 million a year ago supported by a strong decrease of operating working capital. Capital expenditures were EUR 241 million against EUR 204 million a year ago. Net LPS after exceptional items was EUR 0.46 against net EPS after exceptional items of EUR 0.10 a year ago. Sales in the fourth quarter increased 12% compared to fourth quarter of 2012, mainly driven by acquisitions. The company announced the fall in EBITDA was due to actions aimed to reduce inventories and lower sales for the human nutrition and health (HNH) unit, which would have left larger margins had it enjoyed better revenue. DSM Food Specialties also impacted EBITDA. For the year, the company reported net sales of EUR 9,181 million against EUR 8,858 million a year ago. EBITDA was EUR 1,168 million against EUR 1,261 million for the same period a year ago. Core net profit, continuing operations was EUR 492 million against EUR 549 million a year ago. Net profit before exceptional items, continuing operations was EUR 419 million against EUR 497 million a year ago. Net profit after exceptional items, total DSM was EUR 145 million or EUR 0.78 per share against EUR 271 million or EUR 1.52 per share a year ago. Core EPS was EUR 2.85 against EUR 3.19 a year ago. Net EPS before exceptional items, continuing operations was EUR 2.42 against EUR 2.84 a year ago. Cash flow from operations was EUR 808 million against EUR 998 million a year ago. Capital expenditures were EUR 628 million against EUR 629 million a year ago. Net debt was EUR 2,420 million against EUR 1,841 million a year ago. For the year 2015, based on current rates and the 2015 hedge effects, the overall impact of currencies on EBITDA in 2015 would be roughly neutral. Assuming the January 2015 prices persist, the negative impact on DSM’s 2015 EBITDA will be around EUR 80 million. In addition, in 2015 further focus will be given to improve operating working capital management. Taking the above into account, the company aims to deliver an EBITDA in 2015 that is slightly ahead of the result of 2014.

Royal DSM Proposes Dividend for 2014

Royal DSM proposes to maintain the dividend at EUR 1.65 per ordinary share for 2014. This will be proposed to the Annual General Meeting of Shareholders to be held on 30 April 2015. An interim dividend of EUR 0.55 per ordinary share having been paid in August 2014, the final dividend would then amount to EUR 1.10 per ordinary share. The dividend will be payable in cash or in the form of ordinary shares at the option of the shareholder. Dividend in cash will be paid after deduction of 15% Dutch dividend withholding tax. The ex-dividend date is 5 May 2015.

Koninklijke DSM To Sell Caprolactam Business

Koninklijke DSM N.V. (ENXTAM:DSM) is looking to sell its caprolactam business.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RDSMY:US $13.98 USD -0.01

RDSMY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Ashland Inc $127.62 USD -1.59
Celanese Corp $57.11 USD -0.10
Grupo Bimbo SAB de CV $42.22 MXN -0.52
Huntsman Corp $22.46 USD +0.05
Merck KGaA €92.06 EUR +0.238
View Industry Companies
 

Industry Analysis

RDSMY

Industry Average

Valuation RDSMY Industry Range
Price/Earnings 74.5x
Price/Sales 0.9x
Price/Book 1.4x
Price/Cash Flow 12.0x
TEV/Sales 0.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KONINKLIJKE DSM NV-SPONS ADR, please visit www.dsm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.